Search Results

Neuronetics, Inc. announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21.

Neuronetics, Inc. announced significant updates to the NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting system for NeuroStar providers.

Neuronetics, Inc., a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced their participation at the 12th Annual Meeting of the Clinical TMS Society in London, England from June 13th-15th.

Neuronetics, Inc., a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is committed to supporting adolescents facing major depressive disorder.

Neuronetics, Inc. announced that they have received 510 clearance for their obsessive-compulsive disorder Motor Threshold Cap technology for NeuroStar® Advanced Therapy for Mental Health.

Neuronetics, Inc. (NASDAQ: STIM) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has authorized multiple features of NeuroStar TMS (transcranial magnetic stimulation) for sale and distribution in the country – including an expansion of the indication to now include patients with major depressive disorder (MDD) that exhibit comorbid anxiety symptoms, the NeuroStar 3.7 platform, MT Cap, and D-Tect™ MT Accessory.

Neuronetics, Inc. announced a healthcare policy update from National Government Services, Inc. that increases access for patients to its NeuroStar® Advanced Therapy for Mental Health transcranial magnetic stimulation.

Neuronetics, Inc. (NASDAQ: STIM), announced today that they have received 510(k) clearance for their D-Tect™ MT Accessory, which is the latest innovation in NeuroStar’s commitment to simplify the motor threshold determination for physicians.